Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Stocks | Futures | Watchlist | More
or

Verona Pharma Plc ADR (VRNA)

Verona Pharma Plc ADR (VRNA)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 81,498
  • Shares Outstanding, K 13,166
  • Annual Sales, $ 0 K
  • Annual Income, $ -26,560 K
  • 60-Month Beta -0.77
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book 1.73

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 5 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/19
See More
  • Average Estimate -1.12
  • Number of Estimates 3
  • High Estimate -1.02
  • Low Estimate -1.17
  • Prior Year -0.28
  • Growth Rate Est. (year over year) -300.00%

Price Performance

See More
Period Period Low Period High Performance
1-Month
4.96 +24.80%
on 02/04/20
7.40 -16.35%
on 02/14/20
+0.39 (+6.73%)
since 01/24/20
3-Month
3.75 +65.07%
on 12/06/19
12.89 -51.98%
on 12/27/19
+2.20 (+55.14%)
since 11/25/19
52-Week
3.65 +69.59%
on 11/21/19
12.89 -51.98%
on 12/27/19
+0.40 (+6.91%)
since 02/25/19

Most Recent Stories

More News
Verona Pharma plc to Announce Financial Results for Full Year Ended December 31, 2019 and Provide Corporate Update

Verona Pharma plc (AIM: VRP) (Nasdaq: VRNA) ("Verona Pharma"), a clinical-stage biopharmaceutical company focused on respiratory diseases, announces that it will report its audited financial results for...

VRP : 25.65 (-0.97%)
VRNA : 6.19 (-4.92%)
Verona Pharma Announces Publication of Key Phase 2b COPD Data in Respiratory Research

Verona Pharma plc (AIM: VRP) (Nasdaq: VRNA) ("Verona Pharma"), a clinical-stage biopharmaceutical company focused on respiratory diseases, announces publication of Phase 2b clinical trial results for ensifentrine...

VRP : 25.65 (-0.97%)
VRNA : 6.19 (-4.92%)
Verona Pharma Announces Senior Management Changes

Dr. David Zaccardelli appointed President and Chief Executive Officer

VRP : 25.65 (-0.97%)
VRNA : 6.19 (-4.92%)
Global Brain Tumor Drugs Market Expected to Exceed $3 Billion Through 2022

Targeted cancer therapies are drugs or substances which block the growth of cancer by interfering with molecules that are more specifically involved in cancer cell progression than in normal cell activity....

CNSP : 3.99 (-1.93%)
ADAP : 3.45 (+0.88%)
DARE : 1.30 (+1.56%)
VRNA : 6.19 (-4.92%)
PFE : 34.20 (+0.80%)
AXSM : 85.40 (+0.76%)
Verona Pharma Reports Positive Top-line Data in 4 Week Phase 2b COPD Study with Nebulized Ensifentrine on Top of Tiotropium Therapy

Primary endpoint met at all doses: ensifentrine produced clinically and statistically significant dose-dependent improvements in lung function

VRP : 25.65 (-0.97%)
VRNA : 6.19 (-4.92%)
Verona Pharma to Report 4 Week Phase 2b COPD Dose-ranging Study Results with Nebulized Ensifentrine on Top of Tiotropium Therapy

Verona Pharma plc (AIM: VRP) (Nasdaq: VRNA) ("Verona Pharma"), a clinical-stage biopharmaceutical company focused on respiratory diseases, will release results on Monday, January 13, 2020 at 5.00 am GMT...

VRP : 25.65 (-0.97%)
VRNA : 6.19 (-4.92%)
Verona Pharma Appoints David Moskowitz as Vice President, Capital Markets Strategy & Investor Relations

Verona Pharma plc (AIM: VRP) (Nasdaq: VRNA) ("Verona Pharma"), a clinical-stage biopharmaceutical company focused on respiratory diseases, announces the appointment of David Moskowitz to the newly created...

VRP : 25.65 (-0.97%)
VRNA : 6.19 (-4.92%)
Verona Pharma to Present at Jefferies 2019 London Healthcare Conference

Verona Pharma plc (AIM: VRP) (Nasdaq: VRNA) ("Verona Pharma"), a clinical-stage biopharmaceutical company focused on respiratory diseases, announces that Jan-Anders Karlsson, CEO of Verona Pharma, will...

VRP : 25.65 (-0.97%)
VRNA : 6.19 (-4.92%)
Verona Pharma to Participate in Two Upcoming Institutional Investor Conferences in New York

Verona Pharma plc (AIM: VRP) (Nasdaq: VRNA) ("Verona Pharma"), a clinical-stage biopharmaceutical company focused on respiratory diseases, announces that Jan-Anders Karlsson, CEO of Verona Pharma, and...

VRP : 25.65 (-0.97%)
VRNA : 6.19 (-4.92%)
Verona Pharma plc Operational Update and Financial Results for the Three and Nine Months Ended September 30, 2019

Reported positive Phase 2 data with dry powder inhaler formulation

VRP : 25.65 (-0.97%)
VRNA : 6.19 (-4.92%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 64% Buy with a Average short term outlook on maintaining the current direction.

See More Share

Trade VRNA with:

Business Summary

Verona Pharma plc is a clinical-stage biopharmaceutical company. It researches, discovers and develops therapeutic drugs to treat respiratory diseases primarily in the United Kingdom and North America. Verona Pharma plc is based in London, the United Kingdom.

See More

Key Turning Points

2nd Resistance Point 7.25
1st Resistance Point 6.72
Last Price 6.19
1st Support Level 5.86
2nd Support Level 5.53

See More

52-Week High 12.89
Fibonacci 61.8% 9.36
Fibonacci 50% 8.27
Fibonacci 38.2% 7.18
Last Price 6.19
52-Week Low 3.65

See More

Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar